NASDAQ

Omnicell, Inc. (OMCL)

507 Thanks from members

Omnicell (OMCL) shares face a 20.1% monthly pullback despite an upgraded 2026 EPS and revenue outlook, driven by strong Q2 results, operating discipline, and a one-time tariff refund, countered by lingering concerns over memory-chip costs, bookings timing, and hospital purchasing visibility.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →